FDA panel to review popular peptides as wellness demand surges

The U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee is meeting on July 23‑24 to consider whether seven injectable peptides – including BPC‑157, TB‑500, MOTs‑C, Semax and KPV – should be added to the agency’s 503A Bulks List, allowing licensed compounding pharmacies to prepare them for patients with prescriptions.

Scientists on the panel say the compounds lack robust clinical evidence; the FDA’s briefing documents note “little evidence to support the safety or effectiveness” of the peptides. Cell‑biologist Paul Knoepfler warned, “I see it as very risky,” highlighting the absence of large‑scale trials.

The review comes amid a rapid expansion of peptide use in the wellness market, driven by social‑media influencers and endorsements from Health Secretary Robert F. Kennedy Jr., who has called himself “a big fan of peptides.” Industry groups argue that current restrictions have pushed demand into a gray market, with Gary Brecka observing, “When peptides were pulled from the regulated compounding pharmacies, demand didn’t go away.” Companies such as Hims & Hers, Mochi Health and Olympia Pharmaceuticals are preparing for a possible regulatory shift.

The committee’s recommendations are advisory; FDA officials have indicated they may not add the peptides to the list, but the meeting represents a pivotal moment for the burgeoning peptide industry.